Globeflex Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Globeflex Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$493K	Hold	8,719	–	–	0.07%	228
2025 Q4	$518K	Hold	8,719	–	–	0.08%	242
2025 Q3	$472K	Buy	8,719 +6,813	+357%	+$390K	0.07%	250
2025 Q2	$105K	Hold	1,906	–	–	0.01%	370
2025 Q1	$135K	Buy	+1,906	New	+$128K	0.01%	349
2022 Q4	–	Sell	-1,164	Closed	-$99K	–	482
2022 Q3	$99K	Buy	+1,164	New	+$104K	0.02%	398
2022 Q2	–	Sell	-1,462	Closed	-$113K	–	486
2022 Q1	$113K	Buy	+1,462	New	+$122K	0.02%	393
2015 Q3	–	Sell	-4,200	Closed	-$574K	–	503
2015 Q2	$574K	Hold	4,200	–	–	0.11%	294
2015 Q1	$523K	Sell	4,200 -7,840	-65%	-$831K	0.1%	286
2014 Q4	$1.09M	Sell	12,040 -25,900	-68%	-$2.15M	0.21%	201
2014 Q3	$2.74M	Buy	37,940 +34,140	+898%	+$2.24M	0.31%	114
2014 Q2	$236K	Buy	+3,800	New	+$230K	0.03%	342

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Globeflex Capital's BMRN Position: Q1 2026 in Review

Globeflex Capital held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 8,719 shares worth $493K. The position accounts for 0.07% of the portfolio, ranked #228.

Globeflex Capital first reported a position in BMRN in Q2 2014 and has held it in 12 quarters since. The position peaked at $2.74M in Q3 2014. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Globeflex Capital held 8,719 shares of BioMarin Pharmaceuticals worth $493K as of Q1 2026.
Globeflex Capital left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
BioMarin Pharmaceuticals made up 0.07% of Globeflex Capital's portfolio in Q1 2026, its #228 holding.
Globeflex Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 12 quarters since.
Globeflex Capital's BioMarin Pharmaceuticals position peaked at $2.74M in Q3 2014.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.